Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Necitumumab (Portrazza) is indicated in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer.
• Two studies provided a detailed comparison of necitumumab's safety and effectiveness compared to other treatments.
• Studies show mixed results regarding progression-free survival (PFS), with one indicating longer PFS when using necitumumab combined with chemotherapy versus chemotherapy alone, while the other shows no statistically significant improvement.
• In terms of overall survival (OS), both studies suggest potential benefits from adding necitumumab to chemotherapy. This advantage appears more pronounced among patients exhibiting high epidermal growth factor receptor expression according to one study.
• Both studies agree that adding necitumumab leads to a higher incidence and severity of certain adverse events such as skin rash and hypomagnesemia.
• Subgroup considerations indicate that those with high EGFR expression or squamous histology may benefit more from this drug; however, it does not seem beneficial for patients having non-squamous NSCLC in terms of OS or objective response rate.